Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study shows interruption of antiretroviral therapy increases risk of disease and death

04.12.2006
Does not reduce risk of serious side effects from continual ART

Findings from one of the largest HIV/AIDS therapy studies conducted to date show that a specific strategy of interrupting antiretroviral therapy more than doubles the risk of AIDS or death from any cause. Researchers affiliated with the Mailman School of Public Health and Harlem Hospital Hospital led a large multi-center international study, known as Strategies for Management of Anti-Retroviral Therapies, or SMART, comparing two treatment strategies for people with human immunodeficiency virus (HIV). Findings from the study, published in the November 30 New England Journal of Medicine, demonstrate the value of continuous antiretroviral therapy.

As HIV/AIDS has evolved into a chronic disease without a cure, lifelong antiretroviral therapy has become the norm. Lifelong therapy, however, can be difficult to adhere to as well as expensive. For these reasons, there has been a concerted research effort to test treatment interruption strategies that may enhance patients' quality of life and limit adverse drug effects.

The strategies evaluated in the SMART Study compared the recommended continuous use of antiretroviral therapy (anti-HIV medicines) with use of antiretroviral therapy in an episodic (interrupted) manner. The study found that the use of episodic antiretroviral therapy was inferior to continuous therapy as episodic therapy significantly increased the risk of opportunistic diseases or death from any cause. Further, episodic antiretroviral therapy did not reduce the risk of serious complications, including those related to the heart, kidneys, and liver.

Antiretroviral therapy in people with HIV is associated with remarkable benefits including longer survival and less illness. However, life-long treatment is difficult and can be associated with both short- and long-term risks, such as major metabolic and cardiovascular complications and built-up resistance to treatment. According to Wafaa El-Sadr, MD, MPH, co-chair of the SMART Study and professor of clinical Medicine and Epidemiology, "Interruption of antiretroviral therapy has been generally advocated as a potential treatment strategy to enhance the quality of life, limit side effects, and allow for the emergence of the predominant wild-type virus in patients infected with multidrug-resistant HIV. However, our data clearly demonstrate that continuous use of anti-retroviral therapy is superior to its episodic use."

In the SMART Study, researchers from more than 30 countries around the world randomly assigned 5,472 participants infected with HIV with a CD4+ cell count of more than 350 per cubic millimeter to the continuous use of antiretroviral therapy or to the episodic use of antiretroviral therapy. The participants—2,720 in the episodic therapy group and 2,752 in the continuous therapy group—were followed for an average of 16 months. Episodic therapy involved only using antiretroviral therapy when the CD4+ count decreased to less than 250 per cubic millimeter and then stopping therapy when the CD4+ count increased to more than 350 per cubic millimeter. The primary end point was the development of an opportunistic disease or death from any cause. An important secondary end point was major cardiovascular, renal, or hepatic disease.

There were 120 participants in the episodic therapy group and 47 in the continuous therapy group who had an opportunistic disease or died from any cause. Analysis of study data showed that those on episodic therapy had more than twice the risk of developing these endpoints compared to those in the continuous therapy group. In addition, participants in the episodic group experienced significantly more cardiac, renal, and hepatic complications. Observes Dr. El Sadr, "The latter finding is surprising considering that cardiac complications have been associated in other studies with such events and liver and kidney complications have been linked to such treatment."

According to Dr. El-Sadr, "Our findings provide clear and compelling evidence that the episodic antiretroviral strategy, guided by the CD4+ count, should not be recommended." Dr. El-Sadr also stated that further research is needed to evaluate the effect of interrupting antiretroviral therapy on immune function, inflammation, and other markers.

Stephanie Berger | EurekAlert!
Further information:
http://www.columbia.edu

More articles from Studies and Analyses:

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

nachricht Reusable carbon nanotubes could be the water filter of the future, says RIT study
30.03.2017 | Rochester Institute of Technology

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

Im Focus: Using graphene to create quantum bits

In the race to produce a quantum computer, a number of projects are seeking a way to create quantum bits -- or qubits -- that are stable, meaning they are not much affected by changes in their environment. This normally needs highly nonlinear non-dissipative elements capable of functioning at very low temperatures.

In pursuit of this goal, researchers at EPFL's Laboratory of Photonics and Quantum Measurements LPQM (STI/SB), have investigated a nonlinear graphene-based...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

Physicists discover mechanism behind granular capillary effect

24.05.2017 | Physics and Astronomy

Measured for the first time: Direction of light waves changed by quantum effect

24.05.2017 | Physics and Astronomy

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>